Ibudilast regulatory update

MediciNova said FDA granted rare pediatric disease designation to ibudilast, the company’s candidate to treat globoid cell leukodystrophy, or Krabbe disease. The designation is among the criteria that would make MediciNova eligible for a Priority Review voucher under FDA’s rare pediatric disease voucher program, if the therapy is approved. ...